Prosecution Insights
Last updated: October 04, 2026
Application No. 18/276,527

COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF

Final Rejection §102§112
Filed
Aug 09, 2023
Priority
Feb 10, 2021 — provisional 63/147,959 +3 more
Examiner
COLEMAN, BRENDA LIBBY
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Elevatebio Technologies Inc.
OA Round
2 (Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1230 granted / 1643 resolved
+14.9% vs TC avg
Strong +16% interview lift
Without
With
+15.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
52 currently pending
Career history
1670
Total Applications
across all art units

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
8.5%
-31.5% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
52.8%
+12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1643 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 184-187, 192-194, 197-205 and 207-209 are pending in the application. This action is in response to applicants' amendment dated July 7, 2026. Claims 186, 204 and 205 have been amended, claim 206 has been canceled and claims 208 and 209 are newly added. Response to Amendment Applicant's arguments filed July 7, 2026 have been fully considered with the following effect: The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph rejections, labeled paragraph 1d) and e) in the last office action, which are hereby withdrawn. However, with regards to the 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph rejections, labeled paragraph 1a), b) and c) of the last office action, the applicant’s amendments and remarks have been fully considered but they are not persuasive. a, b, and c) The applicants’ stated that claims 186, 204 and 205 are amended to recite “on average 45”. However, on average 45 does not set forth exactly what the value of n is meant to be. What average since there is only one variable n. Claims 186, 204 and 205 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for reasons of record and stated above. In view of the amendment dated July 7, 2026, the following new grounds of rejection apply: Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION. —The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 208 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. The following reasons apply: Claim 208 is vague and indefinite in that it is not known what is meant by the compound of Formula (A-c) where there is not a Formula (A-c) within the claim. Claim 208 is vague and indefinite in that it does not end with a period indicating the end of the claim. Election/Restrictions This application contains claims 187, 192-194, 197-203 and 207 are drawn to an invention nonelected without traverse in the reply filed on February 3, 2026. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 184 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 2283305-20-2 where RP2 is H; LP1 is CH2C(=O)NH; and RP2 is (CH2)7CH3. Claim(s) 184 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 2247447-26-1 where RP2 is H; LP1 is C(=O)O; and RP2 is (CH2)11CH3. Claim(s) 184 and 209 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 226067-30-7 where RP2 is H; LP1 is CH2C(=O)NH; and RP2 is (CH2)13CH3. Claim(s) 184 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 201745-35-9 where RP2 is H; LP1 is CH2CH2C(=O)NH; and RP2 is (CH2)9CH3. Claim(s) 184 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 855477-46-2 where RP2 is H; LP1 is CH2CH2(=O)NH; and RP2 is (CH2)7CH3. Claim(s) 184, 185 and 208 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 791846-99-6 where RP2 is H; LP1 is CH2CH2C(=O)O; and RP2 is (CH2)11CH3. Claim(s) 184 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 226067-29-4 where RP2 is H; LP1 is CH2C(=O)O; and RP2 is (CH2)11CH3. Claim(s) 184 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 201745-33-7 where RP2 is H; LP1 is CH2CH2C(=O)NH; and RP2 is (CH2)11CH3. Claim(s) 184 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 202397-60-2 where RP2 is H; LP1 is CH2CH2C(=O)NH; and RP2 is (CH2)11CH3 disodium salt. Claim(s) 184, 185, 208 and 209 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 70559-30-7 where RP2 is H; LP1 is C(=O)NH; and RP2 is (CH2)16CH3. Claim(s) 184 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 2247447-27-2 where RP2 is H; LP1 is C(=O)O; and RP2 is (CH2)7CH3. Claim(s) 184, 185 and 208 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 308134-20-5 where RP2 is H; LP1 is C(=O)NH; and RP2 is (CH2)11CH3. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENDA L COLEMAN whose telephone number is (571)272-0665. The examiner can normally be reached Mon-Fri 10-6 (flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRENDA L COLEMAN/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Aug 09, 2023
Application Filed
Apr 07, 2026
Non-Final Rejection mailed — §102, §112
Jul 07, 2026
Response Filed
Aug 18, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12740961
USE OF AN ORGANOMETALLIC COMPOUND AS A DNA-DEMETHYLATING AGENT
5y 4m to grant Granted Sep 22, 2026
Patent 12723055
PHOSPHOANTIGEN PRODRUG COMPOUNDS
5y 8m to grant Granted Sep 01, 2026
Patent 12723038
ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE
3y 6m to grant Granted Sep 01, 2026
Patent 12708629
METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS
3y 3m to grant Granted Aug 18, 2026
Patent 12709621
TYK2 INHIBITORS
3y 1m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
90%
With Interview (+15.5%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1643 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month